Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics, Inc. Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular…
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
Opus Genetics, Inc. Robert Gagnon, CFO, Opus Genetics Robert Gagnon, CFO, Opus Genetics RESEARCH TRIANGLE PARK, N.C., Sept.…
AI-Powered Model Can Classify Types of Optic Nerve Damage
TOPLINE: A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among…